Trial Profile

A global phase 3 study evaluating CRV-101 Vaccine

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amezosvatein (Primary)
Indications Herpes zoster
Focus Pharmacodynamics; Registrational
Sponsors Curevo Vaccine

Most Recent Events

07 Jan 2024 According to a Curevo Vaccine media release, based on results from phase 2 trial, company will advance amezosvatein into global Phase 3 trials in 2024 to address a market for shingles vaccination currently exceeding $4 billion.
16 Sep 2022 New trial record
15 Sep 2022 According to Curevo Vaccine media release, this trial expected to begin in 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com